Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • After melanoma...

    After melanoma surgery, Bristols Opdivo offers new care standard

    Written by Ruby Khatun Khatun Published On 2017-09-12T09:15:09+05:30  |  Updated On 18 Aug 2021 2:36 PM IST

    MADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.


    The finding represents an advance for so-called PDx drugs in treating cancer at an earlier stage before it has spread around the body. At present, the use of such drugs, which help the immune system fight tumors, is confined to metastatic disease.


    Doctors use surgery to remove melanomas when possible but such patients remain at high risk of relapse, creating a need for new treatment options.


    So far Yervoy is the only drug approved in the post-surgery or adjuvant setting for this deadliest form of skin cancer, but the high doses of the medicine needed mean it can cause severe side effects and, as a result, use is limited.


    Now results from a large clinical study presented at the European Society for Medical Oncology (ESMO) congress in Madrid show that 71 percent of patients given Opdivo for 12 months lived without disease recurrence against 61 percent for Yervoy.


    The relapse-free survival rate for patients at 18 months was 66 percent against 53 percent.


    Importantly, Opdivo - whose generic name is nivolumab -proved much better tolerated with only 14 percent of patients experiencing severe side effects against 45 percent of those on Yervoy.


    The favorable balance of efficacy and safety means doctors are likely to opt for Opdivo instead of Yervoy, according to Jeffrey Weber of NYU School of Medicine, who was the principal investigator on the study.


    "In the future, I think patients at significant risk of relapse will all be receiving nivolumab," he said. "That will diminish the number of people that relapse and, at the end of the day, I would hope that it will prolong survival."


    The findings, which were also published online in the New England Journal of Medicine, underscore the progress scientists are making against melanoma.


    Another study presented at the ESMO meeting showed a combination of two targeted drugs from Novartis also slashed the risk of melanoma returning after surgery. The Novartis treatment is designed for selected patients with a particular genetic mutation.




    (Reporting by Ben Hirschler; Editing by Mark Potter)



    Bristol-MyersBristol-Myers Squibbcancerdoctorsgenetic mutationmelanomametastatic diseaseNew England Journal of MedicineNovartisOpdivosurgerytumorsYervoy
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok